Loading stock data…
AXGN
$42.04+0.58 (+1.40%)
Market OpenUpdated 3:40 PM EDT
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axogen, Inc. in the Healthcare sector is trading at $42.04. Wall Street consensus targets $50.78 (9 analysts), implying a +20.8% move over the next 12 months. The stock is currently near its 52-week high of $45.83, remaining 42.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$42.04
Potential Downside
0%
Whystock Fair Value$42.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intende...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.85%
Volume
Today's trading volume
719,623
Recent News
Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support
Eli Lilly leads three health care stocks to watch as the market appears to be rotating into medicals. Google stock is finding key support too.
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w
Axogen, Inc. (NASDAQ:AXGN) Analysts Are Pretty Bullish On The Stock After Recent Results
Shareholders of Axogen, Inc. ( NASDAQ:AXGN ) will be pleased this week, given that the stock price is up 12% to...
Axogen Inc (AXGN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses
Axogen Inc (AXGN) reports a robust 26.6% revenue increase in Q1 2026, despite facing higher operating costs and a significant net loss.